Roche's Xofluza may give rise to resistant strains, raising fears of a 'worst case scenario'

In 2018, Shionogi rolled out Xofluza in Japan as a one-dose kill for influenza, with Roche following suit in the US. Soon, though, Japanese regulators noticed the drug was leading to resistant flu strains, and now a new study in Nature confirms the drug leads to specific mutations that may hamper its promise to neutralize the virus in a single dose.